Northline Ibogaine Brief · Independent DeskVol. I · U.S. Policy & AccessEvidence over hype
Independent · Evidence-led · U.S. focusNorthline Ibogaine Brief
Clear, current coverage of U.S. ibogaine access
Editorial Scope

What we cover

Northline provides editorial coverage and reference material — not medical care. Here is the scope of what the Brief tracks.

Policy & legality

We monitor federal scheduling, state-level research initiatives, regulatory announcements and the compliance questions that shape whether — and how — ibogaine can be studied or accessed in the United States. See our legal-status guide.

Safety standards

We explain the screening, cardiac monitoring, contraindication and informed-consent practices that separate responsible programs from unsafe ones, detailed in our safety guide.

Access & research pathways

We outline the two lawful routes — authorized research and licensed treatment abroad — and the logistics and costs of each, in treatment abroad and cost.

Reference & explainers

We maintain plain-language explainers on how protocols work and how outcomes are measured, cross-referencing authoritative sources so readers can verify for themselves — see the process and ibogaine for opioid addiction.

Suggest a topic or correction →